Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Drug</td><td align="center">Effects</td><td align="center">References</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Infliximab, adalimumab,<br/>golimumab, and <br/>certolizumab pegol</td><td align="center">Increased risk of infections </td><td align="center">[<a href="/journals/aps/2013/313858/#B72">70</a>–<a href="/journals/aps/2013/313858/#B74">72</a>]</td></tr><tr><td align="left">Etanercept</td><td align="center">No DDIs</td><td align="center">[<a href="/journals/aps/2013/313858/#B74">72</a>]</td></tr><tr><td align="left">Adalimumab</td><td align="center">No DDIs</td><td align="center">[<a href="/journals/aps/2013/313858/#B77">73</a>]</td></tr><tr><td align="left">Tocilizumab, certolizumab pegol, and golimumab</td><td align="center">No DDIs</td><td align="center">[<a href="/journals/aps/2013/313858/#B79">74</a>–<a href="/journals/aps/2013/313858/#B81">76</a>]</td></tr><tr><td align="left">Abatacept</td><td align="center">No DDIs</td><td align="center">[<a href="/journals/aps/2013/313858/#B82">77</a>]</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

DDIs between MTX’s and biological drugs.

Advances in Pharmacological and Pharmaceutical Sciences

tab5

Table 5

Table 5: Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis 